Science
Rodrigo Sánchez-Bayona: Managing HR+/HER2- Early Breast Cancer in the Genomic Era
Rodrigo Sánchez-Bayona/LinkedIn

Rodrigo Sánchez-Bayona: Managing HR+/HER2- Early Breast Cancer in the Genomic Era

Rodrigo Sánchez-Bayona, Medical Oncologist at 12 de Octubre University Hospital, shared on X:

“New paper on the management of HR+/HER2- early breast cancer in the genomic era!

Here are the real-world outcomes on how intermediate-risk (i-ROR) PAM50 patients fit into the new landscape of adjuvant CDK4/6 inhibitors.”

Title: Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors

Authors: Santiago Terán, María Illia, María Carla Quevedo, Marina López Moreno, Manuel Alva Bianchi, Laura Lema, Cristina González, Pablo Tolosa, Ainhoa Madariaga, Luis Manso, Yolanda Ruano, Lucía Parrilla, María Ángeles Cobos, Eva Ciruelos, Rodrigo Sánchez-Bayona

Read the full article.

FDA Approves Gedatolisib – Based Therapy for HR+/HER2− Advanced Breast Cancer Without PIK3CA Mutation
Rodrigo Sánchez-Bayona: Managing HR+/HER2- Early Breast Cancer in the Genomic Era

Ainhoa Madariaga Breast Cancer cancer Cristina González Eva Ciruelos Laura Lema Lucía Parrilla Luis Manso Manuel Alva Bianchi María Ángeles Cobos María Carla Quevedo María Illia Marina López Moreno OncoDaily Oncology Pablo Tolosa Rodrigo Sánchez-Bayona Santiago Terán Yolanda Ruano